Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 1802-29-5 | MDL No. : | MFCD11855995 |
Formula : | C12H6N4 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | HFGASMNBMUOCGQ-UHFFFAOYSA-N |
M.W : | 206.20 | Pubchem ID : | 11052781 |
Synonyms : |
|
Num. heavy atoms : | 16 |
Num. arom. heavy atoms : | 12 |
Fraction Csp3 : | 0.0 |
Num. rotatable bonds : | 1 |
Num. H-bond acceptors : | 4.0 |
Num. H-bond donors : | 0.0 |
Molar Refractivity : | 56.9 |
TPSA : | 73.36 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | Yes |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | Yes |
Log Kp (skin permeation) : | -6.9 cm/s |
Log Po/w (iLOGP) : | 1.8 |
Log Po/w (XLOGP3) : | 0.92 |
Log Po/w (WLOGP) : | 1.89 |
Log Po/w (MLOGP) : | -0.4 |
Log Po/w (SILICOS-IT) : | 2.41 |
Consensus Log Po/w : | 1.32 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.55 |
Log S (ESOL) : | -2.19 |
Solubility : | 1.34 mg/ml ; 0.0065 mol/l |
Class : | Soluble |
Log S (Ali) : | -2.05 |
Solubility : | 1.85 mg/ml ; 0.00899 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -4.35 |
Solubility : | 0.00925 mg/ml ; 0.0000449 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 2.02 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P261-P305+P351+P338 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
91% | The nitrile based monomer was synthesized according to aslightly adopted procedure reported by Duan et al [32]. In firstinstance, NiCl26H2O (0.12 g, 0.5 mmol) was dissolved in 20 mLdry DMF. The resulting mixture was heated to 40 C and 2-bromo5cyanopyridine (1.83 g, 10.0 mmol), anhydrous LiCl(0.43 g, 10.0 mmol) and Zn powder (0.78 g, 12.0 mmol) wereadded. After raising the temperature to 50 C, a grain of I2 andtwo drops of acetic acid were added into the mixture and stirredfor 30 min. Afterward, the mixture was cooled down to 0 C beforeadding 1 N HCl (15 mL) and stirring it for an additional 30 min. Hereafter, aqueous ammonia (25%) was added to make the mixturealkaline and the resulting product was extracted with ethyl acetate(3 50 mL). The combined organic layers were washed with a 5%aqueous LiCl solution and dried over MgSO4, filtered and concentrated.2,20-bipyridine-5,50-dicarbonitrile was obtained as a palebrown powder in 91% yield (0.94 g). No further purification wasrequired for the next reaction step. 1H NMR (400 MHz, CDCl3): d8.97 (2H, dxd, J = 2.0, 0.8 Hz), 8.64 (2H, dxd, J = 8.3, 0.8 Hz), 8.14(2H, dxd, J = 8.3, 2.1 Hz) (Fig. S1). 13C NMR (100.6 MHz, CDCl3): d157.0, 152.1, 140.5, 121.7, 116.5, 110.7 (Fig. S2). |
[ 1802-28-4 ]
[2,2'-Bipyridine]-5-carbonitrile
Similarity: 1.00
[ 62494-22-8 ]
[2,2'-Bipyridine]-3-carbonitrile
Similarity: 0.88
[ 834881-86-6 ]
[2,4'-Bipyridine]-5-carbonitrile
Similarity: 0.87
[ 1613-71-4 ]
[2,2'-Bipyridine]-4-carbonitrile
Similarity: 0.87